* Entera Bio Ltd ENTX.OQ ENTX.O is expected to show a
rise in
quarterly revenue when it reports results on November 12
(estimated) for the period ending September 30 2024
* The Jerusalem Israel-based company is expected to report
revenue of $40 thousand, according to the estimate from one
analyst, based on LSEG data.
* LSEG's mean analyst estimate for Entera Bio Ltd is for a
loss
of 5 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Entera Bio
Ltd is
$10.00, above its last closing price of $1.75.
This summary was machine generated November 8 at 17:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)